110.72 0.00 (0.00%)
After hours: 4:34PM EST
|Bid||108.55 x 800|
|Ask||112.40 x 800|
|Day's Range||106.16 - 115.40|
|52 Week Range||98.56 - 278.62|
|Beta (3Y Monthly)||2.38|
|PE Ratio (TTM)||15.08|
|Earnings Date||Feb 7, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||220.67|
Viking Therapeutics fell earlier this week after Citron Research released a bearish report on licensor Ligand Pharma, but shares recovered on Thursday.
Bragar Eagel & Squire, P.C. is investigating potential claims against Ligand Pharmaceuticals Incorporated (LGND). Our investigation concerns whether Ligand has violated the federal securities laws and/or engaged in other unlawful business practices. Bragar Eagel & Squire, P.C. is a New York-based law firm concentrating in commercial and securities litigation. For additional information concerning our investigation into Ligand Corporation please go to https://bespc.com/lgnd/.
NEW YORK, Jan. 17, 2019 -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Ligand Pharmaceuticals.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting 52-week highs on Jan. 16) Avenue Therapeutics Inc (NASDAQ: ATXI ) BioDelivery ...
NEW YORK, NY / ACCESSWIRE / January 17, 2019 / Despite concerns of a partial government shutdown, U.S. markets extended gains for the second consecutive session on Wednesday on strong earnings from Bank ...
Failure to prosecute Alleged Multi-Year Accounting and Securities Fraud at Ligand Pharmaceuticals (NASDAQ: LGND) Diminishes SEC Credibility, Warrants Investigation MARLBOROUGH, Mass. , Jan. 16, 2019 /PRNewswire/ ...
Citron Research, the activist short-seller headed by Andrew Left, has dug up some nasty evidence against Ligand Pharmaceuticals Inc. (LGND). In a 23-page report, Citron accused the San Diego-based biopharmaceutical company of misleading investors, adding that its future revenue calculations are a "pipe dream." The short seller then slapped a $35 price target on the stock, implying 80% downside from the report’s publication date. After failing to successfully develop its own drugs, Ligand switched its business model to focus on collecting royalties and milestone payments from compounds and intellectual property that it licenses to other drug developers.
NEW YORK , Jan. 16, 2019 /PRNewswire/ -- Wolf Popper LLP is investigating potential securities fraud claims on behalf of investors in Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) during the period ...
"I don't have a response or a statement at this time, but I will e-mail you anything that Ligand makes public," wrote Bruce Voss, managing director and principal at Ligand, told TheStreet via e-mail. Smaller pharmaceutical companies often receive such payments from larger firms as part of joint ventures, but Citron alleged that listed addresses for two firms Ligand expects to receive large payments from don't appear to host those companies at all.
Ligand Pharmaceuticals stock crashed to nearly a two-year low Wednesday after short-seller Citron Research slammed the biotech stock for having "80% downside from its current levels."
Ligand Pharmaceuticals Inc. (NASDAQ: LGND ) shares were falling Wednesday after Citron Research issued a report alleging that Ligand’s business model is a “pipe dream," saying the company is deceiving ...
SAN DIEGO , Jan. 16, 2019 /PRNewswire/ -- Shareholder Rights Law Firm Johnson Fistel, LLP with the assistance of former California Deputy Attorney General and Special Prosecutor, Tiffany Johnson, Esq. ...
Shares of Ligand Pharmaceuticals Inc. fell more than 20% on Wednesday after famed short seller Andrew Left of Citron Research called the San Diego, Calif., drug company's pipeline a "pipe dream." Ligand "is a company designed for the 'lazy investor' whose stock price has 80% downside from its current levels once people READ," Left said in a note. Ligand has changed its strategy from developing its own drugs to acquiring candidate drugs and technologies and forming partnerships to develop them further. Although the company has generated royalties, they are mostly generated from just four approved drugs with one accounting for more than 75% of royalties, the note said. Shares of Ligand have fallen 32% in the past 12 months, compared with losses around 6% for the S&P 500 index.
Ligand Pharmaceuticals Incorporated announced today plans to report fourth quarter and full year 2018 financial results on February 7, 2019. Ligand’s CEO John Higgins, President and COO Matt Foehr and Executive Vice President and CFO Matt Korenberg will host the conference call.
# Ligand Pharmaceuticals Inc ### NASDAQ NMS:LGND View full report here! ## Summary * Bearish sentiment is high ## Bearish sentiment Short interest | Negative Short interest is extremely high for LGND with more than 20% of shares on loan. This means that investors who seek to profit from falling equity prices are currently targeting LGND. ## Money flow ETF/Index ownership | Neutral ETF activity is neutral. The net inflows of $2.70 billion over the last one-month into ETFs that hold LGND are not among the highest of the last year and have been slowing. ## Economic sentiment PMI by IHS Markit | Neutral According to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, but is easing. ## Credit worthiness Credit default swap CDS data is not available for this security. Please send all inquiries related to the report to firstname.lastname@example.org. Charts and report PDFs will only be available for 30 days after publishing. This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
This means that investors who seek to profit from falling equity prices are currently targeting LGND. Index (PMI) data, output in the Healthcare sector is rising. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way.
Ligand Pharmaceuticals Incorporated (LGND) introduces its financial outlook for 2019. Ligand expects revenue in 2019 to be at least $212 million, with up to an additional $40 million of potential milestone and license payments. Approximately two thirds of the $212 million of revenue is expected to be royalty revenue, and the remainder is expected to consist of contract payments and material sales.
The money will accelerate the development of the company's experimental treatment for pachyonychia congenita.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting 52-week highs on Dec. 17) Endocyte, Inc. (NASDAQ: ECYT ) Down In The Dumps (Biotech ...
Ligand Pharmaceuticals Incorporated (LGND) announces the acquisition of economic rights to PTX-022 from Palvella Therapeutics. PTX-022 is a novel, topical formulation of rapamycin currently in Phase 2/3 development for the treatment of pachyonychia congenita (PC), a rare skin disorder for which no FDA-approved treatment exists. Ligand will pay $10 million to Palvella Therapeutics and in return will receive a tiered royalty on net sales in the mid-to-upper single digits, as well as regulatory and financing milestones.
Vernalis Research, a Ligand Company, announced the achievement of a £1 million success milestone in its drug discovery collaboration with Asahi Kasei Pharma (AKP). This collaboration with AKP was initiated in October 2013 and utilises Vernalis’ fragment and structure-based drug discovery platform against an undisclosed target for rheumatoid arthritis and other autoimmune diseases.
Is Ligand Pharmaceuticals Inc. (NASDAQ:LGND) a good stock to buy right now? We at Insider Monkey like to examine what billionaires and hedge funds think of a company before doing days of research on it. Given their 2 and 20 payment structure, hedge funds have more resources than the average investor. The funds have access […]